Shares of PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) were down 0.7% on Friday . The stock traded as low as $2.12 and last traded at $2.12. Approximately 10,100 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 33,049 shares. The stock had previously closed at $2.13.
PureTech Health Trading Down 0.7 %
The business has a fifty day moving average price of $1.94 and a 200-day moving average price of $2.27.
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
- Five stocks we like better than PureTech Health
- Comparing and Trading High PE Ratio Stocks
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Why Invest in 5G? How to Invest in 5G Stocks
- Top-Performing Non-Leveraged ETFs This Year
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
